companydata.dkFORWARD PHARMA A/S: Financial statements 2016
CVR: 28865880
FORWARD PHARMA A/S (CVR 28865880) has filed annual accounts for 2016. In 2016, the company reported a net result of DKK 2,032,000 compared with DKK -51,065,000 the year before. Equity amounted to DKK 189,657,000. The solvency ratio was 95.2%.
- Profit/Loss
- 2,032,000 kr.
- Equity
- 189,657,000 kr.
- Total Assets
- 199,203,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | - | 2 mio. | 189.7 mio. | - |
| 2015 | - | - | -51.1 mio. | 176.7 mio. | - |
| 2014 | - | - | -13.7 mio. | 238 mio. | - |
| 2012 | - | -11 mio. | 22.4 mio. | 50.4 mio. | - |
How creditworthy is FORWARD PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2016
FORWARD PHARMA A/S has published its annual report for 2015. The net result was DKK -51,065,000.
As of May 6, 2016, Karen Lesley Smith has joined the board of directors of FORWARD PHARMA A/S.
As of May 6, 2016, Duncan Moore has joined the board of directors of FORWARD PHARMA A/S.
As of May 6, 2016, John Kevin Buchi has left the board of directors of FORWARD PHARMA A/S.
As of March 1, 2016, Rupert Sandbrink is registered as director of FORWARD PHARMA A/S.
About FORWARD PHARMA A/S
FORWARD PHARMA A/S was a Danish company of the type Aktieselskab based in Hellerup, founded in 2005 and dissolved in 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company has 4 employees. In 2024, the company reported a gross profit of DKK -9,457,909 and a net result of DKK 75,927,645 compared with DKK -3,832,516 the year before. Equity amounted to DKK 488,330,233.